Last reviewed · How we verify
NCT05797896: i-GAIN
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
trial in Dry Age-related Macular Degeneration in 250 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2027
Quick facts
| Lead sponsor | Complement Therapeutics |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 7 February 2023 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 22 locations across United Kingdom, United States |
Conditions studied
- Dry Age-related Macular Degeneration — all drugs for Dry Age-related Macular Degeneration →
- Geographic Atrophy — all drugs for Geographic Atrophy →
- Retinal Disease — all drugs for Retinal Disease →
- Macular Degeneration — all drugs for Macular Degeneration →
Sponsor
Complement Therapeutics — full company profile →
Who can join
65 and older, any sex, with Dry Age-related Macular Degeneration or Geographic Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05797896
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT06536062 — Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma. · NA · recruiting
- NCT06229665 — Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) · Phase 2, PHASE3 · active not recruiting
- NCT05706896 — Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Pla · NA · recruiting
- NCT04627428 — Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular · Phase 1, PHASE2 · recruiting
- NCT04065490 — Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) · NA · active not recruiting
Other Complement Therapeutics trials
Trials by the same sponsor.
- NCT07392255 — An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geog · Phase 1, PHASE2 · recruiting
- NCT07144137 — A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05797896 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Complement Therapeutics
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05797896.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing